objeCtives: To describe psoriasis treatments in Latin America and the impact of failing to achieve high psoriasis skin clearance. Methods: One hundred and forty-four dermatologists and 941 of their psoriasis patients from Brazil, Colombia, Argentina and Mexico participated in the Adelphi Latin America Disease Specific Programme, answering questions about current disease severity, treatment, satisfaction and treatment history. The Physician's Global Assessment (PGA) identified patients with clear skin or substantial coverage remaining; EQ-5D (5L) questionnaire captured quality of life (QoL); Work Productivity and Activity Impairment (WPAI) questionnaire assessed work productivity. Results: Current psoriasis treatments for the 941 patients were biologic agents (38.4%), conventional systemic treatment (45.4%) or combination of both (13.9%); 38% patients were receiving a steroid and 11% phototherapy. Of those treated with biologics, conventional systemic treatment or combination of both, 42.7%, 63.2% and 45.8% respectively were not considered by the dermatologist to be in remission. Among patients with clear to nearly clear skin (PGA 0-1; n= 343) 86.3% patients currently treated with a biologic were in remission compared with 79.1% treated with a conventional systemic treatment. Compared to patients with substantial skin coverage (PGA 2-5; n= 597), patients in the clear or nearly clear skin group had fewer areas of the body affected in difficult to treat areas such as scalp (19.2% vs 51.9%), groin/genitals (0.6% vs 17.7%) and palmar-plantar regions (11.4% vs 26.6%); had lower incidence of flares (5.2% vs 37%), greater satisfaction (96.5% vs 53.7%); better mean (SD) EQ-5D (5L) (0.87 [0.2] vs 0.77 [0.2]) and mean total WPAI (6.5 [13.7] vs 18.0 [26.5]). ConClusions: Many Latin American patients had substantial skin coverage, even when treated with biologics. More biologictreated patients were in remission than conventional systemic-treated patients. Better skin clearance was associated with improved QoL and work productivity, reflecting the need of treatments providing higher skin clearance. Majority of patients (82.8%) were female, aged mean (SD) 51.9 (13.3) years with mean (SD) disease duration 11.1 (9.4) years. At the time of survey 31.8% patients were classified as moderate-severe based on rheumatologist's judgement despite 98.5% currently receiving a bDMARD or JAK inhibitor. Mean (SD) DAS-28 disease activity was 3.8 (1.4) . Many patients (38.4%) reported via a VAS scale moderate-high levels of pain and were currently experiencing mean (SD) of 3.2 (3.0) symptoms, including joint tenderness (47.3%), swollen joints (46.3%) and morning stiffness (42.2%). The mean (SD) number of joints affected was 4.5 (2.2); wrists (89.1%), MCP joints (85.4%) and knees (62.7%) were most prevalent. According to the rheumatologist, 14.1% patients were flaring at time of survey (defined as temporary worsening of symptoms), and 79.4% were not in remission (defined as DAS-28 < 2.6) irrespective of treatment. The mean (n, SD) EQ-5D 5L utility and EQ-5D VAS scores were 0.7 (509, 0.2) and 70.7 I2: 0.9%; p= 0.388). However, metabolic outcomes were poorly described, preventing a meta-analysis. A mixed treatment comparison corroborated the direct metaanalysis. ConClusions: Considering the high level of risk of bias and the absence of important published outcomes for anti-obesity therapy assessments, this study found that the evaluated drugs showed poor evidence of efficacy in the treatment of overweight and obese patients. Robust safety data were not identified to suggest changes in their regulatory status.
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PSY3 medIcal TreaTmenTS for acromegalY: SYSTemaTIc revIeW and neTWork meTa-analYSIS
Leonart LP, Ferreira VL, Tonin FS, Pontarolo R Universidade Federal do Paraná, Curitiba, Brazil objeCtives: To evaluate the safety and efficacy of medical treatments used in acromegaly. Methods: A systematic search was conducted in the electronic databases PubMed, Scopus, Web of Science, and Scielo. Head-to-head or against placebo randomized controlled trials (RCT) in acromegaly patients were included. Data regarding baseline characteristics, the outcomes insulin-like growth factor 1 (IGF-1) and/or growth hormone (GH) control and adverse events were extracted. The meta-analyses were performed using the software Addis 1.16.8. Results: 10 studies were included in this review. The records involved the drugs Pegvisomant, Lanreotide Autogel, Lanreotide SR, Octreotide, Octreotide LAR, Pasireotide, Bromocriptine, and placebo. A network meta-analysis was performed for the outcome patients with IGF-1 control. Pegvisomant and Lanrotide Autogel showed statistically significant superiority compared to placebo (Odds Ratio with 95% credible interval of 0.06 [0.00-0.55] and 0.09 [0.01-0.88], respectively). No other statistical differences were observed. The probability rank suggested that Pegvisomant and Pasireotide have similar probabilities of being the best drug to control IGF-1 circulating levels (33% and 34%, respectively). It was not possible to build a network for GH outcome because the definition of GH control was not standardized among the studies. Considering adverse events, most of trials reported complaints related to the gastrointestinal tract (e.g., diarrhea and nausea). ConClusions: This was the first meta-analysis to compare high quality evidence (RCT) of medical treatments used in acromegaly. Despite the low number of trials, it was possible to compare the interventions though an indirect analysis. Considering that acromegaly is a rare disease, the publication of interventional studies is not frequent. Thus, we recommend the addition of a control group using a different drug when trials are performed, making the comparison of efficacy between drugs feasible. Pasireotide, newer and cheaper than Pegvisomant, seems to be a promising drug that should be more investigated. 
